TFL Gallery / f-derm-time-to-event

AEF01 · Figure

Time to Dermatologic Event by Treatment Group

The study's only figure: Kaplan-Meier curves for time to a first dermatologic event, by treatment group, with medians, confidence limits and a log-rank test. Xanomeline is delivered transdermally, so this is the tolerability question the delivery route raises.

Slug
f-derm-time-to-event
Regulatory ID
AEF01
Type
Figure
E3 position
§14.2
Status
evidenced
Current iteration
v002
Datasets
adtte 82a036b, adsl 70c7278
Evidence
20/20 passing
Requirements
DSP-ALL-001 DSP-ALL-002 DSP-INTXT-001 DSP-INTXT-002 DSP-INTXT-003 DSP-TTE-001 DSP-TTE-002 DSP-TTE-003 STD-GATE-001 STD-GATE-002 STD-GATE-003 STD-GATE-004 STD-GATE-005 STD-MODEL-001 STD-MODEL-002 STD-MODEL-003 STD-MODEL-004 STD-MODEL-005 STD-SRC-001 STD-SRC-002
Used in
Study model
Safety Analysis Set SAFFL · grouped by TRT01A
Specification
2 iterations
Environment
R 4.3.3 Darwin 23.6.0
Bound by
No text block binds it
Values
No value is sourced from it
Inputs
Function
Outputs

Generated by the same pipeline run that wrote the ARD and the HTML above, from the same rendered cells; the short hash is the manifest's record of the file.

f-derm-time-to-event · post_text variant · study CDISCPILOT01 · data cut-off 2014-07-01

Time to Dermatologic Event by Treatment Group0501001502000.00.20.40.60.81.0Time to Dermatologic Event or End of Study (days)Survival ProbabilityProduct-Limit Survival Function EstimatesPlaceboXanomeline Low DoseXanomeline High DoseLog-rank chi-square 60.27 on 2 df, p <0.0001Number at risk866147400842312608422440
Time to Dermatologic Event by Treatment Group
Study CDISCPILOT01 — Safety Analysis Set
Placebo (N=86) Xanomeline Low Dose (N=84) Xanomeline High Dose (N=84)
Subjects with a dermatologic event, n (%) 29 (34%) 62 (74%) 61 (73%)
Censored, n (%) 57 (66%) 22 (26%) 23 (27%)
Median time to event, days (95% CI) NE 33 (27, 48) 36 (24, 46)
Dermatologic events are the adverse events the study flagged as its first customised query, CQ01NAM = 'DERMATOLOGIC EVENTS'; ADTTE carries one record per subject for the first such treatment-emergent event.
Subjects without a dermatologic event are censored at their study completion date (CNSR = 1); the event time is the day of the first event (CNSR = 0).
Survival probability is the Kaplan-Meier product-limit estimate of remaining free of a dermatologic event. Tick marks on a curve are censored subjects, and the counts beneath it are the subjects still at risk at each of those days.
The median and its 95% confidence limits use the linear transformation, reproducing the limits in the reference report; NE means the curve never reached 0.5 and the median is not estimable.
The test annotated on the figure is the log-rank test of equality across the three treatment groups. Its chi-square and degrees of freedom are stated alongside the p-value so the p-value can be checked rather than taken on trust; the reference report states only that the difference was significant. A p-value smaller than the precision this display declares is reported at that boundary — '<0.0001' — rather than rounded to '0.0000', which would assert a probability of zero. The unrounded value is retained in the analysis results dataset.
The curve, the tick marks, the numbers at risk and the annotated test are drawn from the same committed analysis results dataset as the table beneath them, so no number on this page is a second calculation of another.
Source: adtte, adsl (CDISC pilot ADaM package, vendored from phuse-org/phuse-scripts). Data cut-off: 2014-07-01.
open.csr display f-derm-time-to-event (post_text variant); generated from the committed ARD.

Rendered from outputs/f-derm-time-to-event/v002/table.html.

Every iteration is kept: outputs/f-derm-time-to-event/vNNN/ holds the spec snapshot, the ARD, the rendered output, and a manifest recording who regenerated it, why, and from which commit.